---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-037122"
form_type: "8-K"
ticker: null
cik: "0001603207"
company_name: "Notable Labs, Ltd."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:37:55.508339+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Notable Labs restructures: pauses Phase 2 Volasertib study, cuts 65% of workforce

## Summary
- Board approved streamlined operating plan to explore strategic alternatives for maximizing shareholder value.
- Phase 2 study of Volasertib in relapsed/refractory AML paused immediately.
- Workforce and outside consultants reduced by ~65%; expected completion by September 24, 2024.
- Anticipates ~$0.1 million in charges for termination benefits, recognized in Q3 and Q4 2024.
- Kaile A. Zagger appointed as Chief Restructuring Officer and Interim CEO.

## SEC filing metadata
- accession: 0001493152-24-037122
- form_type: 8-K
- cik: 0001603207
- company_name: Notable Labs, Ltd.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/0001493152-24-037122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-037122
- JSON: https://secwatch.observer/filing/0001493152-24-037122.json
- Plain text: https://secwatch.observer/filing/0001493152-24-037122.txt

## Key facts
- Restructurings & Charges
  Notable Labs, Ltd. announced a restructuring with charges of approximately $0.1 million (approximately 65%).
  - Type: restructuring
  - Charge: approximately $0.1 million
  - Headcount: approximately 65%
  source text: the Board of Directors also approved: (i) immediately pausing the implementation of the planned Phase 2 study of Volasertib in relapsed/refractory AML (r/r AML), and (ii) a reduction in the Company’s employee workforce and outside consultants by approximately 65%, which the Company expects to substantially complete by September 24, 2024. The Company anticipates recognizing approximately $0.1 million in total charges in connection with the reduction in force
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/0001493152-24-037122-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.